The U.S. Food and Drug Administration (FDA) on Friday cleared Dexcom Inc.‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, expanding access to continuous glucose monitoring for younger patients.

The FDA previously cleared Stelo for adults 18 and older in March 2024. The device is now the first over-the-counter continuous glucose monitor authorized for children in this population.

The expanded clearance comes as prediabetes affects a growing number of U.S. children, raising their risk of developing Type 2 diabetes.

Read Also:

Diabetes Tech Player DexCom Lays Out ...